AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02363959
Drug: Hyperbaric Oxygen Therapy
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 hours of breathing \>99% medical grade oxygen inside an air-pressurized chamber at 2 ATA once a day for 20 sessions. These sessions will be scheduled 3-5 times per week, depending on the availability of the patient and the hyperbaric medicine physician.
Trial: NCT01292798
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.05ml of 0.5mg or 2.0mg ranibizumab injected intravitreally
Trial: NCT04023825
Drug: suprazygomatic maxillary nerve block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: in the experimental group, each child will profit from the realization of a suprazygomatic maxillary nerve block.
Trial: NCT04113668
Drug: BMS-986165
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified Dose on Specified Days
Trial: NCT02509845
Drug: C16G2
RxNorm normalized name: Cefuroxime
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antimicrobial peptide
Trial: NCT00940758
Drug: PEP02
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dose escalation: 50-100 mg/m2 biweekly
Trial: NCT01390922
Drug: Botulinum Toxin Type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Botulinum Toxin Type A
Trial: NCT01499953
Drug: Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose: 10 mg Duration: 45 (±5) days Frequency: once daily Application: oral
Trial: NCT01499953
Drug: Fondaparinux
RxNorm normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fondaparinux Dose: 2.5 mg Duration: 45 (±5) days Frequency: once daily Application: subcutaneous
Trial: NCT02338349
Drug: Elacestrant
RxNorm normalized name: Elacestrant
DrugBank: Elacestrant (DB06374)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01965730
Drug: epsilon-aminocaproic acid (EACA)
RxNorm normalized name: Epsilon Aminocaproic Acid
DrugBank: Aminocaproic acid (DB00513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03712683
Drug: Thyroxine
RxNorm normalized name: Thyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thyroxine was prescribed with the diagnosis of SCH and continued when pregnancy was confirmed
Trial: NCT00326027
Drug: Pantoprazole
RxNorm normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efficacy of Pantoprazole
Trial: NCT00926393
Drug: Quetiapine Immediate Release
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral, 3 tablets daily: (2 x 25 mg + 1 x 50 mg) at one time each day
Trial: NCT03077919
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5% ropivacaine
Trial: NCT04533321
Drug: Afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Afatinib is approved therapy for SCC of the lung after progression with standard of care chemotherapy.
Trial: NCT00926393
Drug: Quetiapine Extended Release
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral, 3 tablets daily: (2 x 25 mg + 1 x 50 mg) at one time each day
Trial: NCT02771717
Drug: Budesonide (Pulmicort)
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide (Pulmicort) - inhaled low dose inhaled steroid - I puff to be taken twice daily
Trial: NCT04102995
Drug: Sepranolone injection low dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Sepranolone (DB12972)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) administration
Trial: NCT04102995
Drug: Sepranolone injection high dose
RxNorm normalized name: high-density polyethylene
DrugBank: Sepranolone (DB12972)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) administration
Trial: NCT03738618
Drug: Follitropin delta
RxNorm normalized name: follitropin delta
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: FE 999049 was administered as single daily subcutaneous injections in the abdomen at a starting dose of 15 μg daily that was fixed for the first four stimulation days. Based on ovarian response, the dose could be adjusted by 3 μg, with dose increases implemented not more frequently than once every 2 days and dose decreases implemented per investigator's judgement. The minimum daily dose was 6 μg, and the maximum daily dose was 24 μg.~Participants could be treated for a maximum of 20 days. Coasting, use of dopamine agonist or any other drug to prevent early ovarian hyperstimulation syndrome (OHSS) with the exception of gonadotropin-releasing hormone (GnRH) agonist for triggering of final follicular maturation, was not allowed
Trial: NCT00007358
Drug: Dexamethasone or other corticosteroid
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered during the third trimester of pregnancy
Trial: NCT01018485
Drug: Botulinum Toxin Type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Intramuscular injection in affected limb up to 100 Units. Two doses (one placebo, one active) 3 months apart.
Trial: NCT00301418
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tarceva®: Will be given at a starting dose of 150mg QD dose for the first cycle which is 28 days. This will be followed by 14 days of 100mg PO on a bid schedule and 150mg PO on a bid schedule for the final 14 days of the second cycle. Assuming no dose limiting toxicity, 150 mg PO tid will be continued for up to 10 more cycles. This is an outpatient regimen, in which the drug is admininistered orally. Tumor response will be assessed after every 2nd treatment cycle. Patients may receive a maximum of 12 cycles of treatment under this research protocol.
Trial: NCT00826618
Drug: ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: This is an open-label, Phase I study of intravitreally administered 0.5mg ranibizumab in subjects with uveitic CME.
Trial: NCT02023255
Drug: JNJ-39393406
RxNorm normalized name: JNJ-39393406
DrugBank: JNJ-39393406 (DB11867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part A of the study, participants will receive single dose of JNJ-39393406 50 mg, 150 mg, 450 mg, 1,350 mg, and 2,700 mg once daily for 7 consecutive days. In Part B of the study, participants will receive single dose of JNJ-39393406 based on the PK data from Part A of the study once daily for 13 consecutive days.
Trial: NCT04459377
Drug: S-Ketamine
RxNorm normalized name: S-ketamine
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients are randomized to three groups. Randomization in blocks of six patients stratified by sex. A list of serial numbers and randomized group affiliation is produced which is open to the pharmacy's manufacturing staff and closed to the staff of the trial. The pharmacy prepares filled syringes with investigation drug in accordance with randomized group affiliation.~All groups are sedated with midazolam intravenously to a defined end point. A syringe pump with volume accuracy ± 2% injects the test drug (P, K1 or K2). One infusion set is coupled between the syringe and a three-way connection, which in turn is connected to a peripheral venous catheter (PVK). This PVK is also used for blood sampling. Blood is sampled at two occasions. Directly preoperatively and two hours after surgery. The third molar is surgically removed.
Trial: NCT04459377
Drug: Sodium Chloride 0.9% Inj
RxNorm normalized name: SODIUM CHLORIDE 0.9% INJ
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients are randomized to three groups. Randomization in blocks of six patients stratified by sex. A list of serial numbers and randomized group affiliation is produced which is open to the pharmacy's manufacturing staff and closed to the staff of the trial. The pharmacy prepares filled syringes with investigation drug in accordance with randomized group affiliation.~All groups are sedated with midazolam intravenously to a defined end point. A syringe pump with volume accuracy ± 2% injects the test drug (P, K1 or K2). One infusion set is coupled between the syringe and a three-way connection, which in turn is connected to a peripheral venous catheter (PVK). This PVK is also used for blood sampling. Blood is sampled at two occasions. Directly preoperatively and two hours after surgery. The third molar is surgically removed.
Trial: NCT00816283
Drug: dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 50 mg orally 2 times per day or 140 mg orally one time per day
Trial: NCT00816283
Drug: vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg orally 2 times per day
Trial: NCT00006116
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00006116
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01281540
Drug: Cisapride
RxNorm normalized name: Cisapride
DrugBank: Cisapride (DB00604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one 10 mg tablet 4 times a day for 8 weeks
Trial: NCT00003346
Drug: acetylcysteine
RxNorm normalized name: Acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003346
Drug: carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02673619
Drug: Umeclidinium
RxNorm normalized name: Umeclidinium
DrugBank: Umeclidinium (DB09076)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Umeclidinium (GSK573719) 1.85% will be supplied as a clear, colourless solution, free from visible particulates, for topical application. Each subject total daily dose will be calculated as per study reference manual (SRM) using subject's hand area. A single dose of study treatment will be based on the size of the subject's hand in order to provide coverage of approximately 2µL/ cm\^2. If certain pre-specified criteria for safety and tolerability are met, consideration will be given to decreasing the dose by decreasing the concentration of the topical formulation to 1.15% for the remaining subjects.
Trial: NCT02799212
Drug: somatostatin infusion
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: postoperative somatostatin infusion during 5 days at 6mg/day, followed by one day at 3mg/day.
Trial: NCT02008227
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1200 mg IV infusion on Day 1 of each 21-day cycle
Trial: NCT02008227
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m\^2 IV infusion on Day 1 of each 21-day cycle
Trial: NCT03161106
Drug: Lactulose
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lactulose plus diet consumed by patient
Trial: NCT03495102
Drug: Dulaglutide
RxNorm normalized name: DULAGLUTIDE
DrugBank: Dulaglutide (DB09045)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered SC
Trial: NCT04157712
Drug: ALZ-801 or matching placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02453503
Drug: Licorice
RxNorm normalized name: Licorice
DrugBank: Licorice (DB10675)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: licorice mucoadhesive films evey 6 hours for two weeks
Trial: NCT02453503
Drug: Triamcinolone Acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide mucoadhesive films 1 mg every 6 hours for two weeks.
Trial: NCT01769196
Drug: Simtuzumab
RxNorm normalized name: Simtuzumab
DrugBank: Simtuzumab (DB12152)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg/mL single-dose vials administered subcutaneously once a week
Trial: NCT01769196
Drug: Simtuzumab placebo
DrugBank: Simtuzumab (DB12152)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simtuzumab placebo single-dose vials administered subcutaneously once a week
Trial: NCT00627367
Drug: Hydromorphone
RxNorm normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydromorphone 1mg IV, followed by an optional dose of 1mg IV hydromorphone 15 minutes
Trial: NCT03646370
Drug: Tenofovir Alafenamide
RxNorm normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients with HIV infection who are virally suppressed receiving a tenofovir disoproxil fumarate-based antiretroviral therapy regimen that switched to tenofovir alafenamide without switching any other components of their treatment regimen.
Trial: NCT00308269
Drug: Vintafolide IV Bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Vintafolide (DB05168)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vintafolide is a folic acid desacetylvinblastine hydrazide conjugate
Trial: NCT00308269
Drug: Vintafolide IV Infusion
RxNorm normalized name: Duo Fusion
DrugBank: Vintafolide (DB05168)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vintafolide is a folic acid desacetylvinblastine hydrazide conjugate
Trial: NCT03675139
Drug: Medroxyprogesterone Acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At a dosage of 10mg/day
Trial: NCT03675139
Drug: Dydrogesterone 10 MG
RxNorm normalized name: dydrogesterone 10 MG
DrugBank: Dydrogesterone (DB00378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At a dosage of 20 mg/day
Trial: NCT01756417
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: One 1,000 mg tablet of metformin taken orally (by mouth) on Day 1 and Day 8.
Trial: NCT01756417
Drug: Canagliflozin (JNJ-28431754)
RxNorm normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Four 25 mg tablets of canagliflozin (JNJ-28431754) taken orally on Days 4 through 8.
Trial: NCT04055909
Drug: nangibotide low dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Nangibotide (DB16247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nangibotide 0.3 mg/kg/h
Trial: NCT04055909
Drug: nangibotide high dose
RxNorm normalized name: high-density polyethylene
DrugBank: Nangibotide (DB16247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nangibotide 1.0 mg/kg/h
Trial: NCT00196365
Drug: levonorgestrel/EE 0.15/0.03 mg tablets and placebo
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 tablet daily
Trial: NCT03960658
Drug: ketamine-enhanced prolonged exposure
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single infusion of racemic ketamine at 0.5mg/kg (ideal body weight) for 40 minutes. The next day, patients will have a standardized prolonged exposure session which lasts approximately 90 minutes. This co-jointed intervention will be repeated for 3 weeks. Then, patients will continue with therapy sessions to complete a total of 10-12 sessions.
Trial: NCT00904488
Drug: Addition of oral Metolazone
RxNorm normalized name: Metolazone
DrugBank: Metolazone (DB00524)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Addition of oral metolazone 5 mg daily to continued current dose of intravenous bolus furosemide
Trial: NCT00904488
Drug: Furosemide dose escalation
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide dose escalation via either IV bolus (2-2.5 x current dose) or continuous infusion (2-2.5 x current dose administered over previous 24 hours)
Trial: NCT02445326
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03005548
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In Sham comparator group All eligible patients will be treated with patient-controlled IV morphine analgesia (PCA) (PCA pump (CADD-Legacy PCA Pump (Deltec, Inc.) morphine IV bolus 1 mg, lockout time 10 mins).~Device: wireless tDCS (StarStim, NeuroElectrics) non-invasive brain stimulation with a pair of electrodes with saline-soaked pads for delivery of direct current at intensity 2 mA for 30s at the beginning.
Trial: NCT00536471
Drug: Duloxetine hydrochloride
RxNorm normalized name: Duloxetine Hydrochloride
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03458780
Drug: Yellow Fever Vaccine
RxNorm normalized name: yellow fever vaccine
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yellow Fever Vaccine .5 ml
Trial: NCT00533039
Drug: Varespladib (A-002)
RxNorm normalized name: Varespladib
DrugBank: Varespladib (DB11909)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250mg tablets BID for 3-5 days pre-angioplasty and 5 days post-angioplasty.
Trial: NCT00520104
Drug: intranasal ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: drug interaction
Trial: NCT00036634
Drug: Tenofovir DF
RxNorm normalized name: LAMIVUDINE 300MG/TENOFOVIR DF 300MG TAB
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tenofovir DF tablet administered orally once daily
Trial: NCT00036634
Drug: Tenofovir alafenamide
RxNorm normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tenofovir alafenamide tablet(s) administered orally once daily
Trial: NCT01903018
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00193206
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 2000 mg/m2 IV D1 q 14 days x 6 cycles
Trial: NCT00193206
Drug: Epirubicin
RxNorm normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epirubicin 50 mg/m2 D1 q 14 days x 6 cycles
Trial: NCT00474669
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel will be administered in normal-saline delivered at an inflow temperature of 42 degreesC for 90 minutes by the technique described in Appendix D of the protocol
Trial: NCT02952001
Drug: 4 mg CLS-TA Suprachoriodal Injection
RxNorm normalized name: Ta
DrugBank: Tantalum (DB12859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This drug was administered in the Parent study, CLS1001-301 (NCT02595398). No study treatments were administered during this observational extension study.
Trial: NCT00193206
Drug: Albumin-bound Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ABI-007 175 mg/m2 D1 q 14 days x 6 cycles
Trial: NCT01873716
Drug: Indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indocyanine green (ICG) for injection, 0.25mg/kg intravenously. A maximum of 25mg is given, approximately 30-60 minutes before carotid endarterectomy
Trial: NCT00695617
Drug: trisodiumcitrate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: trisodiumcitrate 1.035 M
Trial: NCT01500850
Drug: human insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.~human insulin: bolus injections before each main meal
Trial: NCT01500850
Drug: Insulin Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.
Trial: NCT01500850
Drug: Insulin glulisine
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.~Insulin glulisine: bolus injections before each main meal
Trial: NCT02047214
Drug: TPI 287
RxNorm normalized name: TPI-287
DrugBank: TPI-287 (DB17168)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPI 287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class. TPI 287 is an Investigational Drug.
Trial: NCT02047214
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avastin (bevacizumab) is an FDA approved drug indicated for multiple cancers, including as a single agent for GBM for adult patients with progressive disease following prior therapy. Single agent effectiveness is based on improvement in objective response rate; no data is available demonstrating improvement in disease-related symptoms or survival with bevacizumab.
Trial: NCT01969955
Drug: nanoparticle albumin-bound paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nanoparticle albumin-bound paclitaxel is given at 130 mg/m2 intravenously on day 1 and 8, every 21 days.